Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Top Cited Papers
- 5 December 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 394 (10215), 2184-2196
- https://doi.org/10.1016/s0140-6736(19)33041-7
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialThe Lancet, 2015
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver DiseaseGastroenterology, 2013
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortalityJournal of Hepatology, 2011
- Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel diseaseGut, 2011
- Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meaningsJournal of Hepatology, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisThe New England Journal of Medicine, 2010
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory responseJournal of Hepatology, 2008
- Gamma Glutamyl Transferase and Metabolic Syndrome, Cardiovascular Disease, and Mortality RiskArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Design and validation of a histological scoring system for nonalcoholic fatty liver diseaseJournal of Hepatology, 2005